Abstract Library

#4380 Cell-free DNA concentration correlates with copy number variant (CNV)-count, describes tumour progression and nuclear instability in GEP-NETs

Introduction: Cell-free DNA (cfDNA) levels depend on various factors related to the shedding of cells and might provide valuable information on tumour state and treatment success. In a genomic profiling pilot study conducted as part of the COMPOSE Phase III multicentre open-labelled clinical trial we assessed multiple factors and their impact on cfDNA levels in 14 GEP-NET patients.

Conference:

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Capdevila J, Smutna V, Weckwerth W, Erdoe M,

Keywords: CNV, cfDNA, liquid biopsy, quantitative marker, cfDNA concentration, longitudinal, GEP-NET, genomic profiling,

#4331 Amino acid-induced hyperkalaemia during peptide receptor radionuclide therapy (PRRT): A case report and literature review

Introduction: PRRT an established treatment for neuroendocrine tumours (NETs). Therapy requires prophylactic positively charged amino acid (AA) co-infusion to reduce renal radiation exposure. AA infusion has been associated with metabolic acidosis and electrolyte abnormalities, particularly hyperkalaemia; comprehensive data on the prevalence and severity of these complications remains limited.

Conference:

Presenting Author:

Authors: Osher E, Wolf I, Geva R, Sofer Y, Greenman Y,

Keywords: PRRT, hyperkalaemia, amino acid infusion, neuroendocrine tumour, adverse effects,

#3672 Impact of everolimus starting dose on antiproliferative efficacy in patients with neuroendocrine tumors – Experiences from a tertiary referral center

Introduction: Everolimus is approved at a full dose of 10 mg daily for the treatment of advanced neuroendocrine tumors (NETs) but associated with relevant toxicities. Hence dose reductions are a frequent event in clinical practice.

Conference:

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Melhorn P, Macheiner S, Wolff L, Kretschmer-Chott E,

Keywords: everolimus, dose reduction, advanced NET, systemic therapy, medical oncology,

#1680 PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).

Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lamarca A

Authors: Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J,

Keywords: immunotherapy,

#1545 In Vivo Expression of Survivin and XIAP in Medullary Thyroid Carcimoma

Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5 % of all thyroid malignancies. Although surgery remains the first line therapy with curative intention, for advanced MTC current chemotherapeutic regimes do not provide promising results. Consequently, the identification of biologically relevant biomarkers that are associated with MTC progression may provide novel therapeutic targets.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Werner T

Authors: Werner T, Riemer J, Dizdar L, Wolf A, Cupisti K,

Keywords: MTC, IAP, survivin, XIAP,